- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06302205
A Home-based Exercise and Physical Activity Intervention After Liver Transplantation: Impact of Exercise Intensity (PHOENIX-L)
A Home-based Exercise and Physical Activity Intervention After Liver Transplantation: Impact of Exercise Intensity - a Monocenter Randomized Controlled Trial [PHOENIX-Liver]
Research demonstrated that transplant recipients benefit from physical activity, but there is a gap in knowledge regarding the required intensity. In the PHOENIX-Liver study, researchers aim to investigate the adequate intensity of rehabilitation programs after liver transplantation. Patients will be randomized into one of the three PHOENIX-Liver training groups (low, moderate, moderate to high). The six months rehabilitation program is conducted from the patient's home but supervised by a PHOENIX-investigator.
At baseline, after three months of rehabilitation and after six months of rehabilitation, a test moment takes place at which physical fitness, cardiovascular health, liver function, and body composition will be assessed. Questionnaires are taken monthly to survey well-being, safety, quality of life, physical activity, and cost-effectiveness.
To gather information on the potential for implementation in a real-world setting, a 15-month-long physical activity phase will start after the intervention phase. This entails a maintenance physical activity program tailored to the patients' preferences. A follow-up at UZ Leuven is planned at three and at 15 months where the same clinical evaluations will be conducted as during the test moments of the intervention phase.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Diethard Monbaliu, MD PhD
- Phone Number: +3216342361
- Email: diethard.monbaliu@uzleuven.be
Study Contact Backup
- Name: Stefan De Smet, PhD
- Email: stefan.desmet@kuleuven.be
Study Locations
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgium, 3000
- Recruiting
- UZ Leuven
-
Principal Investigator:
- Diethard Monbaliu, MD PhD
-
Contact:
- Hanne Van Criekinge
- Phone Number: +3216343162
- Email: hanne.vancriekinge@kuleuven.be
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- de novo adult liver transplant recipients with a transplant vintage of two to three months
- access to a home freezer (± -18°C)
Exclusion Criteria:
- Aberrant CPET (abnormal low cardiorespiratory fitness is not considered an exclusion criteria), unstable angina, life-threatening arrhythmias, uncontrolled hypertension/diabetes, HbA1c ≥ 9%, severe pulmonary disease (FEV1 < 50%), musculoskeletal disorders not allowing physical training on a cycle ergometer, or any other medical reasons by the physician considered to be a contraindication for moderate or high-intensity physical exercise
- multi-organ transplantation (exception: combined liver-kidney transplant is considered eligible for participation)
- ongoing treatment for malignancies
- unable to understand Dutch
- no access to smartphone and/or computer with internet access
- does not willing to except the general conditions of Coachbox. Preparticipation medical screening (cardiopulmonary exercise testing with 12-lead ECG + stratification of cardiovascular risk factors) will be performed by a cardiologist (Dr. Kaatje Goetschalckx at UZ Leuven).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Sham Group
Home-based low-intensity exercise training without subsequent physical activity intervention.
|
2 times a week, flexibility and balance training
|
Experimental: Moderate-intensity (MIT)
Home-based moderate-intensity exercise training with subsequent physical activity intervention.
|
The home-based training intervention consists of two phases of each three months in duration.
It consists of three weekly aerobic training sessions on the one hand, and two weekly training sessions focused on strength, balance, and flexibility on the other hand.
|
Experimental: Combined moderate and high-intensity (MHIT)
Home-based moderate- and high-intensity exercise training with subsequent physical activity intervention.
|
The home-based training intervention consists of two phases of each three months in duration.
It consists of three weekly aerobic training sessions on the one hand, and two weekly training sessions focused on strength, balance, and flexibility on the other hand.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiorespiratory fitness
Time Frame: At 0, 3 and 6 months of the interventional rehabilitation programme and at 15 months after the end of the intervention
|
Changes in peak oxygen uptake (mL O2·min-1·kg-1) assessed by cardiopulmonary exercise test
|
At 0, 3 and 6 months of the interventional rehabilitation programme and at 15 months after the end of the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional exercise capacitiy
Time Frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
six-minute walking test (m)
|
At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
Hand grip strength
Time Frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
assessement by means of Jamar Hydraulic Hand Dynamometry (kg)
|
At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
Knee-extensor strength
Time Frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
assessement by means of Biodex dynamometer (Nm)
|
At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
Endothelial function
Time Frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
assessed via flow mediated dilation
|
At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
Arterial stiffness
Time Frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
assessed via pulse wave velocity
|
At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
Graft function
Time Frame: At 0 and after 21 months
|
Transient elastography Fibroscan assessing liver stiffness
|
At 0 and after 21 months
|
Occurence of adverse events
Time Frame: Monthly
|
Safety is estimated by means of questionnaires
|
Monthly
|
Motor fitness
Time Frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
Short Physical Performance Battery test
|
At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
Blood pressure
Time Frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
Variation in blood pressure measured by means of automatic device (Omron M6) in fasted condition and without medication taken in
|
At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention
|
Blood profile
Time Frame: At 0, 3 and 6 months of the interventional rehabilitation programme, and at 3 and 15 months after the end of the intervention
|
Blood is drawn when patient is in fasted condition and did not take their medication
|
At 0, 3 and 6 months of the interventional rehabilitation programme, and at 3 and 15 months after the end of the intervention
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- S66232
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplantation
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingLiver Transplantation | Kidney TransplantationFrance
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
-
Rennes University HospitalCompletedLiver Transplantation | Kidney TransplantationFrance
Clinical Trials on Physical activity
-
Health Education Research Foundation (HERF)CompletedQuality of LifePakistan
-
Zohra Institute of Health SciencesCompletedPhysical Activity and StressPakistan
-
Cardenal Herrera UniversityRecruiting
-
Istituti Clinici Scientifici Maugeri SpAActive, not recruiting
-
Centre Hospitalier Universitaire DijonWithdrawn
-
AUSL Romagna RiminiFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRecruitingNon-Small Cell Lung CancerItaly
-
Fundación para la Investigación del Hospital Clínico...CompletedObesity | Severe Mental Disorder
-
Augusta UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Kansas... and other collaboratorsCompletedMental Disorders, SevereUnited States
-
Centre Hospitalier Departemental VendeeTerminated
-
Rio de Janeiro State UniversityCompleted